Frequency and clinical features of deficient mismatch repair in ovarian clear cell and endometrioid carcinoma.
Adenocarcinoma, Clear Cell
Endometrioid
Lynch Syndrome
Microsatellite Instability
Ovarian Cancer
Journal
Journal of gynecologic oncology
ISSN: 2005-0399
Titre abrégé: J Gynecol Oncol
Pays: Korea (South)
ID NLM: 101483150
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
17
05
2021
revised:
20
04
2022
accepted:
12
06
2022
entrez:
29
8
2022
pubmed:
30
8
2022
medline:
31
8
2022
Statut:
ppublish
Résumé
To clarify the frequency of deficient mismatch repair (dMMR) in Japanese ovarian cancer patients, we examined microsatellite instability (MSI) status and immunohistochemistry (IHC) subtypes, including endometrioid carcinoma (EMC), clear cell carcinoma (CCC), or a mixture of both (Mix). We registered 390 patients who were diagnosed with EMC/CCC/Mix between 2006 and 2015 and treated at seven participating facilities. For 339 patients confirmed eligible by the Central Pathological Review Board, MSI, IHC, and MutL homolog 1 methylation analyses were conducted. The tissues of patients with Lynch syndrome (LS)-related cancer histories, such as colorectal and endometrial cancer, were also investigated. MSI-high (MSI-H) status was observed in 2/217 CCC (0.9%), 10/115 EMC (8.7%), and 1/4 Mix (25%). Additionally, loss of MMR protein expression (LoE-MMR) was observed in 5/219 (2.3%), 16/115 (14.0%), and 1/4 (25%) patients with CCC, EMC, and Mix, respectively. Both MSI-H and LoE-MMR were found significantly more often in EMC (p<0.001). The median (range) ages of patients with MMR expression and LoE-MMR were 54 (30-90) and 46 (22-76) (p=0.002), respectively. In the multivariate analysis, advanced stage and histological type were identified as prognostic factors. The dMMR rate for EMC/CCC was similar to that reported in Western countries. In Japan, it is assumed that the dMMR frequency is higher because of the increased proportion of CCC.
Identifiants
pubmed: 36032025
pii: 33.e67
doi: 10.3802/jgo.2022.33.e67
pmc: PMC9428302
doi:
Substances chimiques
MutL Protein Homolog 1
EC 3.6.1.3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e67Subventions
Organisme : National Hospital Organization of Japan
Informations de copyright
© 2022. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.
Déclaration de conflit d'intérêts
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. No potential conflict of interest relevant to this article was reported.
Références
Genet Test Mol Biomarkers. 2014 Apr;18(4):229-35
pubmed: 24592941
Pathology. 2011 Aug;43(5):420-32
pubmed: 21716157
Oncogene. 2007 Jul 5;26(31):4541-9
pubmed: 17260015
BMC Cancer. 2018 May 21;18(1):576
pubmed: 29783979
Gynecol Oncol. 2006 May;101(2):238-43
pubmed: 16360201
Fam Cancer. 2005;4(4):301-5
pubmed: 16341807
Am J Surg Pathol. 2010 Dec;34(12):1798-804
pubmed: 21107085
Scand J Gastroenterol. 2011 Nov;46(11):1340-8
pubmed: 21879804
Cancer Sci. 2018 Nov;109(11):3411-3415
pubmed: 30142704
Am J Surg Pathol. 2019 Feb;43(2):235-243
pubmed: 30256257
J Mol Evol. 2010 Mar;70(3):266-74
pubmed: 20213140
Eur J Hum Genet. 2012 Jul;20(7):762-8
pubmed: 22274583
J Clin Oncol. 2008 Dec 10;26(35):5783-8
pubmed: 18809606
Cancer Treat Rev. 2016 Dec;51:19-26
pubmed: 27838401
Hum Pathol. 2017 Dec;70:121-128
pubmed: 29107668
Cancer Prev Res (Phila). 2012 Feb;5(2):320-7
pubmed: 22086678
Am J Surg Pathol. 2008 Jul;32(7):1029-37
pubmed: 18469706
Crit Rev Oncol Hematol. 2013 Oct;88(1):154-67
pubmed: 23562498
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
J Mol Diagn. 2011 May;13(3):271-81
pubmed: 21497289
Lancet. 1971 Jul 17;2(7716):163
pubmed: 4104488
Genetics. 1998 Apr;148(4):1637-46
pubmed: 9560383
Gynecol Oncol. 2018 Apr;149(1):146-154
pubmed: 29496294
Histopathology. 2016 Aug;69(2):288-97
pubmed: 26799366
Ann Oncol. 2017 Jan 1;28(1):96-102
pubmed: 27742654
Gynecol Oncol. 2020 Mar;156(3):669-675
pubmed: 31924330
Cancer Res. 2008 Oct 15;68(20):8541-6
pubmed: 18922929
Br J Cancer. 2012 Nov 6;107(10):1783-90
pubmed: 23047549
JAMA Oncol. 2019 Apr 01;5(4):551-555
pubmed: 30452494
Gynecol Oncol. 2011 May 1;121(2):353-7
pubmed: 21324516
Mod Pathol. 2006 Nov;19(11):1414-20
pubmed: 16941012
Gynecol Oncol. 2001 Aug;82(2):223-8
pubmed: 11531271
Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13629-34
pubmed: 8942985
Int J Gynecol Pathol. 2012 Nov;31(6):524-31
pubmed: 23018216
Lancet Oncol. 2012 Apr;13(4):385-94
pubmed: 22361336
J Mol Diagn. 2008 Jul;10(4):293-300
pubmed: 18556767